MoneyWorks4Me

Lupin informs about updates

20 Sep 2025 Evaluate

Lupin has informed that the U.S. FDA has conducted a product-specific Pre-Approval Inspection at the Company’s Pune Biotech facility from September 08 to September 19, 2025. The inspection closed with four observations. The company will address the observations and respond to the U.S. FDA within the stipulated timeframe. The company is committed to be compliant with CGMP quality standards across all its facilities.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1860.00
Dr. Reddys Labs. 1250.00
Cipla 1383.00
Lupin 2060.00
Zydus Lifesciences 1195.20
View more..